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Abstract
Background: Aberrant expression of small noncoding RNAs called microRNAs (miRNAs) is a common feature of several
human diseases. The objective of the study was to identify miRNA modulation in patients with complex regional pain
syndrome (CRPS) a chronic pain condition resulting from dysfunction in the central and/or peripheral nervous systems.
Due to a multitude of inciting pathologies, symptoms and treatment conditions, the CRPS patient population is very
heterogeneous. Our goal was to identify differentially expressed miRNAs in blood and explore their utility in patient
stratification.
Methods: We profiled miRNAs in whole blood from 41 patients with CRPS and 20 controls using TaqMan low
density array cards. Since neurogenic inflammation is known to play a significant role in CRPS we measured
inflammatory markers including chemokines, cytokines, and their soluble receptors in blood from the same
individuals. Correlation analyses were performed for miRNAs, inflammatory markers and other parameters including
disease symptoms, medication, and comorbid conditions.
Results: Three different groups emerged from miRNA profiling. One group was comprised of 60% of CRPS patients
and contained no control subjects. miRNA profiles from the remaining patients were interspersed among control
samples in the other two groups. We identified differential expression of 18 miRNAs in CRPS patients. Analysis of
inflammatory markers showed that vascular endothelial growth factor (VEGF), interleukin1 receptor antagonist
(IL1Ra) and monocyte chemotactic protein-1 (MCP1) were significantly elevated in CRPS patients. VEGF and IL1Ra
showed significant correlation with the patients reported pain levels. Analysis of the patients who were clustered
according to their miRNA profile revealed correlations that were not significant in the total patient population.
Correlation analysis of miRNAs detected in blood with additional parameters identified miRNAs associated with
comorbidities such as headache, thyroid disorder and use of narcotics and antiepileptic drugs.
Conclusions: miRNA profiles can be useful in patient stratification and have utility as potential biomarkers for pain.
Differentially expressed miRNAs can provide molecular insights into gene regulation and could lead to new
therapeutic intervention strategies for CRPS.
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Complex regional pain syndrome (CRPS) is a disabling
chronic neuropathic pain syndrome that can affect one or
more extremities. The broad spectrum of symptoms
includes pain, inflammation, sensory dysfunction, impaired
motor function, and trophic disturbances [1-4]. CRPS is
subdivided into CRPS-I (reflex sympathetic dystrophy) and
CRPS-II (causalgia), based on the absence or presence of
documented nerve injury respectively [5]. The complex
multifactor pathogenesis of CRPS includes inflammatory,
vascular, sympathetic nervous system, cortical, and spinal
mechanisms. The pathophysiology of CRPS is not comple-
tely understood and the diagnosis is based solely on clini-
cal observations. Not all disease mechanisms are equally
prominent in each patient and no single therapeutic mod-
ality is sufficient to attenuate all of the symptoms.
Small nonprotein coding endogenous ~22 nucleotide
RNA molecules called microRNAs (miRNAs) have
attracted considerable attention in an effort to dissect the
molecular changes in various disease models. miRNAs
play important roles in the regulation of gene expression
and function by binding to the 3’ untranslated region (3’-
UTR) of target messenger RNAs (mRNAs) that, in turn,
causes cleavage or repression of translation of these
mRNAs. Each miRNA species regulates multiple genes,
and most mRNA targets contain multiple miRNA bind-
ing sites within their 3’-UTR, suggestive of a complex
regulatory network [6]. As aberrant miRNA expression is
a common feature in a variety of human diseases, these
molecules offer novel avenues for the identification of
biomarkers and new opportunities for the discovery and
validation of novel therapeutic targets [7].
It was recently demonstrated that miRNAs are present
in the serum and plasma of humans and other mammals,
such as rats, mice, cows and horses [8,9]. This finding
opens up the feasibility of using miRNAs as biomarkers of
disease. Though the stability of miRNAs in serum was the
initial concern, it has now been demonstrated that these
circulating miRNAs are protected from plasma RNase
activity and are, in fact quite stable [8]. The existence of
tumor-related miRNAs in serum indicates the potential
usefulness of miRNAs as clinical diagnostic biomarkers of
various cancers [10]. In another recent report, dozens of
stable miRNAs were detected in saliva and two miRNAs
were present in significantly lower levels in the saliva of
patients with oral squamous cell carcinoma compared to
control subjects [11]. Further evidence for the presence of
miRNAs in body fluids came from an analysis of urine
samples [12]. Four miRNAs were significantly elevated in
urine from urothelial bladder cancer patients, demonstrat-
ing the utility of miRNAs as a noninvasive diagnostic
option [13]. All of these studies illustrate the potential use
of miRNAs as novel biomarkers amenable to clinical diag-
nosis in translational medicine [12,14-16]. Biomarkers can
be used to determine the propensity to develop a disease,
measure its progress, or predict prognosis [17]. In clinical
trials, biomarkers can help in patient stratification and
thereby increase the chances of a successful outcome by
targeting the appropriate population. In addition, biomar-
kers can pave the way to individualize treatment and
thereby usher in a new era in personalized medicine [18].
A number of studies have addressed miRNA changes in
rodent models of inflammatory and neuropathic pain
indicating an essential role for miRNAs in altering pain
threshold [19-25]. Although deregulation of miRNA is
now a well-established phenomenon in a number of
human diseases including osteoarthritis pain [26], there
are, to our knowledge, no published reports investigating
the role of miRNA expression in patients with neuro-
pathic pain. The objective of this study was to investigate
differential expression of miRNAs in blood from patients
with CRPS as an initial step to determine its utility as a
novel approach to biomarker development. Correlation
studies also were performed using miRNA profiles,
inflammatory markers and other disease parameters.
Eighteen miRNAs were significantly different between
patients and control subjects compared to three inflam-
matory and immune related markers. Clustering of 60%
of patients with CRPS on the basis of the miRNA profile
suggests that clinically relevant stratification of the
patient population is possible on the basis of alterations
in miRNA expression.
Methods
Standard protocol approvals, registrations, and patient
consents
All subjects were enrolled after giving informed consent as
approved by the Drexel University College of Medicine
Institutional Review Board.
Inclusion and exclusion criteria
Patients with CRPS were recruited from the pain clinic of
Drexel University College of Medicine and fulfilled the
International Association for the Study of Pain (IASP)
diagnostic criteria for CRPS [5]. Healthy control subjects
were recruited from the general public. The exclusion cri-
teria for all subjects included pregnancy, recent infection,
lupus erythematosus, HIV/AIDS, rheumatoid arthritis,
recent extracorporeal circulation (hemodialysis, bypass
surgery, plasmapheresis), bone marrow transplant, immu-
nosuppressive therapy, blood disorders (anemia, leukemia),
thymectomy, or sarcoidosis.
Patient evaluation
All patients with CRPS received a complete neurological
examination and pain evaluation (performed by RJS).
Overall pain levels were determined on a 0-10 numerical
rating scale (NRS) (0 = no pain, 10 = worst possible
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of CRPS in years, age of onset, and medications (narco-
tics, antiepileptics, antidepressants, and anxiolytics). The
presence of other conditions such as radiculopathy, heart
disease, arthritis, irritable bowel syndrome, high blood
pressure, seizure disorder, spinal disk disease, high cho-
lesterol, generalized anxiety disorder, depression, gastroe-
sophageal reflux disease, migraines, and thyroid disease
was also noted. Medical historya n ds e l f - r e p o r t e dv a l u e s
for height and weight were obtained from normal healthy
control subjects. Blood samples were collected from 41
patients while they were taking their current medications
and from 20 controls.
miRNA profiling
Whole blood was collected in PAXgene blood RNA tubes
(BD Biosciences, Bedford, MA). RNA was isolated using a
PAXgene blood miRNA kit (Qiagen, Valencia, CA) follow-
ing the manufacturer’s protocol. RNA concentration was
measured using Nanodrop 1000 (NanoDrop Technologies,
Wilmington, DE).
Taqman Low Density Array (TLDA) microfluidic cards
version A and B (Applied Biosystems, Foster City, CA)
w e r eu s e dt op r o f i l em i R N A sa n dt h ep r o t o c o lr e c o m -
mended by the vendor was followed. We used 50 ng of
total RNA in each reaction for cDNA synthesis using a
TaqMan microRNA reverse transcription kit and human
megaplex RT primers for Pool A and Pool B. Preamplifica-
tion was done using TaqMan preamplification master mix
and human megaplex preamplification primers corre-
sponding to Pool A and Pool B. TLDA cards were assayed
on an ABI PRISM 7900 Sequence detector using universal
thermal cycling conditions of 50°C for 2 minutes, 95°C for
10 minutes, then 40 cycles of 95°C for 15 seconds and 60°
C for 1 minute. The threshold level for background detec-
tion in SDS software was manually set to 0.2.
Data analysis
Quantile normalization was applied to the cycle threshold
(CT) values. Samples with CT values 32 and above were
treated as undetected as recommended by the vendor.
Fold change was calculated from raw CT values using the
2
-ΔΔCT method [27]. The mean of the CT values of the 10
miRNAs with the lowest standard deviation was used as
the endogenous control in the calculation of ΔCT. Statisti-
cal significance of differences in ΔCT values between
CRPS patients and controls was calculated by a 2-tailed
independent samples t-test. The Benjamini-Hochberg false
discovery rate correction [28] was applied to the p-values.
Pairwise Spearman correlation was calculated between
various clinical markers and miRNAs. Hierarchical cluster-
ing of miRNAs and samples was performed along with the
generation of a heatmap of miRNA expression. The sam-
ples were clustered into three groups on the basis of their
miRNA expression levels and the correlations of other
variables against these three groups were calculated.
Determination of Cytokines/Chemokines and Their
Soluble Receptors
The plasma was separated by centrifugation (3000 g for 15
minutes at 4°C), split into 250 μL aliquots and stored at
-70°C. The Milliplex Map high sensitivity 10 plex human
cytokine kit (Millipore, Billerica, MA) was used to deter-
mine plasma levels of the following cytokines: interferon-
gamma (IFNg); the interleukins IL-1b,I L - 2 ,I L - 4 ,I L - 5 ,
IL-6, IL-7, IL-8, and IL-10; and tumor necrosis factor
alpha (TNFa). The Milliplex Map human soluble cytokine
receptor panel (Millipore, Billerica, MA) was used to
determine the following soluble receptors: soluble glyco-
protein 130 (sgp130) (a subunit of the IL-6 receptor com-
plex); the interleukin soluble receptors sIL-1RI, sIL-1RII,
sIL-2Ra, sIL-4R and sIL-6R; the TNFa soluble receptors
sTNFRI and sTNFRII; and sRAGE, the soluble receptor
for advanced glycation end products (AGEs). The plasma
levels of the interleukin-1 receptor antagonist (IL1Ra) and
the chemokine monocyte chemotactic protein-1 (MCP1)
were determined with the Fluorokine MAP Multiplex
Human Cytokine Panel A (R&D Systems, Minneapolis,
MN). Assay results were determined on a Luminex-200
(Luminex, Austin, TX).
Results
The average age of controls and patients was 42 ± 12.7
and 45 ± 11.7 years, respectively. The female to male ratio
was 14/6 for controls and 27/14 for patients with CRPS.
Average body mass index (BMI) for controls and patients
was 24.12 and 28.58 respectively indicating normal BMI
for control and obesity in our CRPS patient population.
miRNA alterations in CRPS
Two-tailed t-tests were used to identify differential expres-
sion of miRNAs between patients and control samples.
The fold changes and p values of significantly altered miR-
NAs are shown in Table 1. A clustergram of the samples
and miRNAs identifying sample subpopulations with
respect to the significant differentially expressed miRNAs
is shown in Figure 1 as a heat map of the log-transformed
fold changes. Heat maps are commonly used for visualiza-
tion of high-dimensional data in a two-dimensional image
with colors representing the intensity values. It is typically
used in gene expression analysis to represent the level of
expression of many genes across a number of comparable
samples. Clustering based on the fold change of significant
miRNAs resulted in a clear separation of patient-only
population from the rest of the subjects. A total of 60% of
the patients (the right half of clustering) showed differen-
tial regulation for these miRNAs (mostly down regulation),
whereas the rest of the patients were more heterogeneous
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which showed considerable variability.
Inflammatory markers
Analysis of inflammatory markers including chemokines,
cytokines and their soluble receptors in blood from the
same individuals showed changes in several markers
(Additional file 1). Though there were trends, t-tests (Ben-
jamini-Hochberg adjustment of p values for multiple com-
parisons) showed that only VEGF, ILR1a and MCP1 levels
were significantly elevated in CRPS patients (Figure 2).
VEGF and ILR1a were significantly correlated with the
reported pain levels of the patients. VEGF also had a sig-
nificant correlation with BMI (Additional file 1).
Analysis of subset of patients with CRPS
Since 60% of the CRPS patients segregated based on
miRNA profile (Figure 1 group 3), we analyzed this sub-
group of patients further. Additional miRNAs that were
identified to be significantly altered are shown in Table 2.
For inflammatory and immune related markers, correla-
tions of significance were observed for IL-6, IL-8, IL1Ra,
MCP1 and VEGF when considering all CRPS patients
versus control samples. Comparing subpopulation
group3 against other samples identified additional corre-
lations for IL-4, IL-5, and TNFalpha. However IL-6, IL-8
Table 1 Fold changes and p values of significantly
altered miRNAs
miRNA Fold change p value
hsa-miR-939 -4.59358 5.55E-06
hsa-miR-25# -3.92328 1.09E-06
hsa-let-7c -2.53502 2.07E-05
hsa-let-7a -2.45923 0.002308
hsa-let-7b -2.40344 5.49E-05
hsa-miR-320B -2.0527 6.91E-06
hsa-miR-126 -2.02362 0.002469
hsa-miR-629.A -1.71231 0.000653
hsa-miR-664 -1.54881 0.001487
hsa-miR-320 -1.44273 7.28E-05
hsa-miR-1285 -1.41594 0.003077
hsa-miR-625# -1.33174 0.003542
hsa-miR-532-3p -1.27226 0.001226
hsa-miR-181a-2# -1.25927 0.000229
RNU48 1.348125 0.000391
hsa-miR-720 1.476853 0.003243
RNU44 1.854213 0.000904
hsa-miR-1201 2.14584 3.17E-05
Fold changes and p values of significantly altered miRNAs (minus sign
indicates down-regulation; data sorted based on fold change). The statistical
significance was calculated using 2-tailed t-tests on the miRNA expressions in
CRPS patients versus control samples.
Group 1                Group 2                               Group 3 
Figure 1 Differential expression of miRNAs in blood from CRPS patients and control samples. A clustergram of the samples and miRNAs
identifying sample subpopulations with respect to the significant differentially expressed miRNAs. A total of 60% of the patients (Group 3)
showed differential regulation for these miRNAs (mostly downregulation), whereas the rest of the patients were more heterogeneous and
clustered together with the control samples. P and C represent patients and controls, respectively. Red, high; black, average; green, low.
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ing the patient population on the basis of the miRNA
profile resulted in changes, predominantly toward the
identification of additional indicators that could be clini-
cally relevant in CRPS.
Correlation analysis
We performed additional correlation analyses of all
miRNAs detected in whole blood with other parameters
including comorbidities. In addition to being in the list
of 18 miRNAs identified to be differentially expressed in
patients with CRPS, hsa-miR-532-3p was associated with
CRPS type, pain level, IL1Ra, and VEGF (Table 3 and
Additional file 1). CPRS Type-2 patients from our study
had higher hsa-miR-532 and higher VEGF levels com-
pared to CRPS Type-1 patients. We observed a strong
correlation between miRNAs and comorbidities such as
high blood pressure, cholesterol, thyroid disease, and
use of narcotics and antiepileptic medications (Table 3
and Additional file 1). These miRNAs did not overlap
with the miRNAs that were modulated in CRPS (Table
1). Though not our primary objective, these results iden-
tified miRNA alterations that may be specific to comor-
bid conditions observed in patients with CRPS. A Circos
diagram [29] capturing the significant correlations
among all parameters analyzed are shown in Figure 3.
Discussion
We observed differential expression of 18 miRNAs in
whole blood from patients with CRPS compared to con-
trol samples. Thus multiple miRNAs were significantly
different between patients and control subjects com-
pared to three inflammatory and immune related mar-
kers. Clustering of 60% of patients with CRPS on the
basis of the miRNA profile suggests that clinically rele-
vant stratification of the patient population is possible
on the basis of alterations in miRNA expression. miR-
NAs recognize their target mRNAs using the 2-8
nucleotide sequence at the 5’ region of the miRNA
called the seed sequence. Target prediction algorithms
use different parameters to provide candidate target
genes for miRNAs [30]. Our earlier success with Tar-
getScan [23] led us to use TargetScan [31] to perform
our initial analysis for miRNAs identified to be differen-
tially expressed in CRPS (data not shown). Bioinformatic
prediction of the significantly altered miRNAs showed
that these miRNAs can potentially modulate mRNAs of
a number of genes relevant in CRPS including inflam-
matory mediators, ion channels, and G protein-coupled
receptors. For example, a bioinformatics-based predic-
tion indicates that hsa-miR-939 can target vascular
endothelial growth factor A (VEGF A), inducible nitric
oxide synthase 2A, and the alpha subunit of voltage-
gated sodium channel type IV and that hsa-miR-25 can
target endothelin receptor type B. Since one of the pre-
dicted gene targets for hsa-miR-939 is VEGF A, the
upregulation of VEGF in the serum of CRPS patients
strengthens the prediction. Additional studies including
reporter gene assays to validate these predictions and
functional consequences of miRNA alterations can
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Figure 2 Elevation of inflammatory markers in CRPS patients. VEGF, IL1Ra, and MCP1 showed significant differential expression in CRPS
patients vs. control samples, with p values 0.0002, 0.0004, and 0.0005, respectively. The error bars show the standard error of the means.
Table 2 Significantly altered miRNAs for samples
Variable p value Variable p value
hsa-miR-25# 9.29E-09 hsa-miR-20a# 0.00454
hsa-let-7c 4.33E-08 hsa-miR-16-1# 0.005137
hsa-let-7b 7.35E-08 hsa-miR-106b 0.00535
hsa-miR-320 6.06E-07 hsa-miR-532-3p 0.00535
hsa-miR-181a-2# 6.64E-05 hsa-miR-142-5p 0.005419
hsa-miR-190b 0.0006 hsa-miR-342-5p 0.005419
hsa-miR-221 0.000721 has-miR-155 0.00595
hsa-miR-629 0.002053 hsa-miR-130b 0.007069
hsa-miR-93 0.002053 hsa-miR-185 0.007069
hsa-miR-590-5p 0.002053 hsa-miR-181c 0.007069
hsa-miR-29b-2# 0.00306 hsa-miR-20b 0.007154
hsa-miR-181a 0.003087 hsa-let-7a 0.009386
hsa-miR-144# 0.003087 hsa-miR-422a 0.009471
hsa-miR-196b 0.003908 hsa-miR-340 0.009501
hsa-miR-132 0.004131 hsa-miR-324-3p 0.009501
hsa-miR-652 0.004131 hsa-miR-598 0.009975
hsa-let-7g 0.004305 hsa-let-7d 0.009975
Significantly altered miRNAs for samples that clustered in Group 3, based on
the miRNA profiling. The statistical significance was calculated using 2-tailed t-
tests on the miRNA expression levels in patients that were in Group 3 versus
other CRPS patients and control samples.
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miRNAs in CRPS.
The miRNAs shown in Figure 1 from the CRPS study
were compared with miRNAs altered in some of the
rodent models for pain investigated. While there was no
overlap in the miRNAs identified from studies that
focused on a limited number of miRNAs, [19-22,25]
profiling from dorsal root ganglion (DRG) from the rat
spinal nerve ligation (SNL) model [23] showed that the
expression of four miRNAs hsa-miR-126, hsa-let-7a,
hsa-let-7b and hsa-let-7c (multiple copies of let-7 family
of miRNAs are present in the genome; isoforms are dis-
tinguished by a letter placed after let-7 to indicate a
slightly different sequence) was significantly altered in
Table 3 Correlation studies in CRPS patients for miRNAs, comorbidities and medication
Variable 1 Variable 2 Correlation p value
CRPS type hsa-miR-532-3p 0.4448 0.00782
CRPS duration hsa-miR-151-5P 0.45992 0.00574
Pain level hsa-miR-296-5p 0.50218 0.00222
hsa-miR-361-3p 0.48489 0.00333
hsa-miR-532-3p 0.46868 0.00478
hsa-miR-30d 0.43451 0.00957
Inmamov (inability to initiate and maintain fine movements) hsa-miR-218 0.46241 0.00546
High blood pressure hsa-miR-92a -0.5583 0.0005
hsa-miR-484 -0.4422 0.00822
High cholesterol hsa-miR-219-1-3p -0.4847 0.00334
hsa-miR-204 0.46688 0.00497
Headache hsa-miR-150 0.49815 0.00245
Thyroid disease hsa-miR-616 0.57271 0.00039
hsa-miR-548d-3p 0.48307 0.00391
hsa-miR-27a 0.45319 0.00733
hsa-miR-345 0.45319 0.00733
hsa-miR-324-5p 0.45319 0.00733
hsa-miR-192 0.45319 0.00733
hsa-miR-28-5p 0.44821 0.00808
hsa-miR-502-5p 0.44821 0.00808
Hyposthesia hsa-let-7c 0.45198 0.00677
hsa-miR-500 -0.4379 0.00897
Narcotics hsa-miR-339-5p 0.54176 0.0008
hsa-miR-191 -0.5248 0.00125
hsa-miR-191# 0.49502 0.00264
hsa-miR-486-3p 0.45677 0.00614
EpilepticDrugs hsa-miR-339-3p 0.56671 0.00039
hsa-miR-30c 0.49587 0.00258
hsa-miR-192 0.4917 0.00285
hsa-miR-140-3p 0.48337 0.00344
hsa-miR-152 0.4667 0.00498
hsa-miR-339-5p 0.45003 0.00704
hsa-miR-145# 0.43337 0.00978
BMI hsa-miR-296-5p 0.41312 0.00239
hsa-miR-1290 -0.3842 0.00507
hsa-miR-423-5p 0.38146 0.00544
hsa-miR-25# 0.3774 0.00599
hsa-miR-1270 0.35921 0.00918
All additional correlations observed including inflammatory markers, groups1, 2 and 3 based on miRNA profiling, clinical parameters etc. are shown in
Supplementary table 1
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369 miRNAs was performed in rat DRG 4 weeks post
SNL [23], whereas the current study profiled 758 miR-
NAs. Thus, not all miRNAs identified in the present
CRPS study have been profiled in rat DRG. This finding
is an indication of the potential translational value that
can be achieved from miRNA profiling.
Expression of small nucleolar RNAs (snoRNAs)
RNU44 and RNU48 was found to be altered in CRPS
patients. RNU44 and RNU48 have been widely used for
negative correlation                                        positive correlation  
Figure 3 Circos diagram showing the correlation of selected parameters and miRNAs. The Circos diagram showing the correlation of
selected medical conditions with other clinical parameters and miRNAs. The nodes along the circle are colored by the total strength of
correlation of the corresponding variable, such that variables with many strong correlations are shown in red. The links between variables
indicate their correlation. Only correlations with adjusted p value less than 0.01 are shown. Groups of miRNAs showing similar correlations with
other variables are labeled as “miRNAs” for brevity. The links are colored by the Spearman’s correlation value, with strong negative correlations
shown in darker blue (e.g., narcotics vs. hsa-miR-191) and strong positive correlations shown in darker red (e.g., pain level vs. “IL1ra, VEGF,
miRNAs”), as implicated by the color-bar. See the Supplementary table 1 for a complete list of correlations.
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that normalizing miRNA expression data to these
recommended snoRNAs introduced bias in associations
between miRNA and pathology or outcome [32]. Their
function is not well understood, but recent reports sug-
gest that the noncoding growth arrest-specific transcript
5 gene (GAS5), which encodes multiple snoRNAs, is sig-
nificantly downregulated in breast cancer [33]. GAS5 is
necessary and sufficient for the arrest of T-cell growth
and for the inhibitory effects of rapamycin and its analo-
gues. It has been suggested that these effects may be
mediated through the snoRNAs. These observations
have important clinical implications because these com-
pounds are used in immunosuppression and in cancer
therapy [34].
Though the pathophysiology of CRPS is not completely
understood, it is known that neurogenic inflammation
plays a significant role [35]. Studies suggest that trauma-
induced release of inflammatory cytokines facilitates neu-
rogenic inflammation [35,36]. Mast cells, neutrophils and
macrophages are recruited to the injured area and
because of the compromised blood-nerve barrier they
invade the nerve [37]. These cells release proinflamma-
tory cytokines that have been implicated in the genera-
tion of neuropathic pain either by direct sensitization of
nociceptors or indirectly by stimulating the release of
agents that act on neurons and glia [38,39]. Thus both
neuroinflammation and neuroimmune activation act in
concert in persistent pain states [40]. The balance
between pro- and anti-inflammatory cytokines may ulti-
mately determine the chronic pain state [41]. An increase
in the level of proinflammatory cytokine IL-2 and a
decrease in the level of anti-inflammatory cytokines IL-4
and IL-10 were reported in CRPS [42,43]. However, sys-
temic inflammatory cytokine responses have been incon-
sistent between the different study populations and
settings. Trends toward an increase in proinflammatory
cytokines (IL-6, IL-8, TNF alpha) and a decrease of the
anti-inflammatory cytokine IL-10 in CRPS subjects com-
pared with the controls have been observed but none of
the changes reached statistical significance [44]. It has
not yet been established clinically that measurement of
plasma cytokines is helpful in the diagnosis or follow-up
of CRPS patients. However, in a recent study using a
large patient population, clustering patterns showed that
plasma cytokine levels should not be evaluated in isola-
tion and that their effect may differ depending on the
plasma level of their soluble receptors and receptor
antagonists [45]. When all CRPS patients were analyzed
only VEGF, MCP1 (CCL2) and IL1Ra were significantly
regulated whereas grouping patients based on miRNA
profiling (Group 3) resulted in additional markers that
were significantly altered including TNFalpha, IL-4 and
IL-5. miRNAs associated with comorbidities and medica-
tions (Table 3) were different from those associated with
CRPS.
We observed hsa-mir-150 to be correlated with head-
ache and several other miRNA correlations with comor-
bidities such as high blood pressure, thyroid disorder,
use of medications including narcotics and antiepileptic
drugs. These results indicate the broader utility of per-
forming miRNA profiling and could provide additional
molecular insights into disease biology occurring as
comorbidities or use of specific medications.
Our studies indicate that miRNA profiling can serve as
a novel approach for patient stratification. Stratification
based on the miRNA profile resulted in identification of
additional markers that were not significant when all
CRPS patients were analyzed as a single group. Stratifica-
tion of patients can be clinically relevant in CRPS and
additional patterns could emerge with increase in sample
size. The potential for identifying several miRNAs as sig-
natures rather than relying on one specific biomarker will
increase the chances of successful treatment in the het-
erogeneous CRPS patient population. Identifying infor-
mative benchmarks will be an exceptionally valuable tool
for assisting physicians in choosing treatment options
and for stratifying patients in clinical trials. By perform-
ing similar miRNA profiling in animal models to cross
validate the human data, we can gain further insight into
mechanistic aspects of CRPS. miRNAs or the genes they
modulate can be direct targets for future therapeutic
interventions. Bridging preclinical and clinical results
could provide new insights into the molecular mechan-
isms underlying chronic pain.
The functional relevance of the presence of stable miR-
NAs in blood is an area of active investigation. A recent
study demonstrated a novel mechanism of intercellular
communication involving the transport and delivery of
miRNAs [46]. Intercellular communication was thought
to be limited to cell-to-cell adhesion conduits (gap junc-
tions) or secreted signals such as hormones and neuro-
transmitters; however, it has been shown that miRNAs
are transported in plasma and delivered to recipient cells
by high-density lipoproteins resulting in modulation of
target mRNAs [46]. Delivery of miRNAs to recipient cells
with functional gene regulatory consequences via blood
opens up novel avenues for target intervention. Identifi-
cation and functional validation of mRNAs modulated by
miRNAs altered in the blood of patients with CRPS can
thus demonstrate the potential for miRNA to regulate
the expression of pain-relevant genes. These studies can
lead to a greater understanding of the molecular mechan-
isms involved in chronic pain and potentially determine if
any of the miRNAs or the genes they modulate can be
direct targets for future therapeutic interventions.
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The ability to cluster 60% of the patients with CRPS
suggests that miRNA profiling can serve as a novel,
clinically relevant approach for patient stratification.
Grouping patients based on miRNA profiling resulted in
the identification of additional markers that were not
significant when the whole CRPS population was con-
sidered. This could be due to the etiology as well as the
multitude of pathologies and symptoms associated with
CRPS. Correlational studies linking miRNA changes
with inflammatory markers and clinical parameters pro-
vided a broad overview of the interplay of multiple fac-
tors critical in CRPS. Additional studies validating the
role of the miRNAs in gene regulation can help to
obtain insights into molecular mechanisms underlying
CRPS.
Additional material
Additional file 1: Correlation studies for miRNAs, comorbidities and
medication. Significant correlations observed including 1) miRNA and
clinical parameters, 2) miRNA and inflammatory markers, 3) miRNA and
groups, 4) inflammatory and immune related markers, and 5) clinical
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3 based on differential expression of miRNAs.
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